Prospera Private Wealth LLC Acquires Shares of 1,049 Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Prospera Private Wealth LLC acquired a new position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 1,049 shares of the company’s stock, valued at approximately $42,000.

Several other institutional investors have also modified their holdings of IONS. Acadian Asset Management LLC purchased a new stake in Ionis Pharmaceuticals during the 1st quarter worth about $255,000. CANADA LIFE ASSURANCE Co raised its position in shares of Ionis Pharmaceuticals by 2.7% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 41,880 shares of the company’s stock worth $1,817,000 after acquiring an additional 1,099 shares in the last quarter. Advisors Asset Management Inc. lifted its stake in Ionis Pharmaceuticals by 948.8% during the first quarter. Advisors Asset Management Inc. now owns 3,178 shares of the company’s stock worth $138,000 after purchasing an additional 2,875 shares during the last quarter. Paloma Partners Management Co acquired a new position in Ionis Pharmaceuticals in the first quarter valued at approximately $213,000. Finally, Kennedy Capital Management LLC increased its stake in Ionis Pharmaceuticals by 9.2% in the first quarter. Kennedy Capital Management LLC now owns 249,527 shares of the company’s stock valued at $10,817,000 after purchasing an additional 21,102 shares during the last quarter. 93.86% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. StockNews.com downgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, November 12th. Needham & Company LLC restated a “buy” rating and issued a $60.00 price objective on shares of Ionis Pharmaceuticals in a research note on Thursday, November 7th. The Goldman Sachs Group raised their price objective on Ionis Pharmaceuticals from $33.00 to $37.00 and gave the stock a “sell” rating in a report on Friday, August 2nd. Barclays boosted their target price on Ionis Pharmaceuticals from $45.00 to $51.00 and gave the company an “equal weight” rating in a report on Friday, August 2nd. Finally, BMO Capital Markets lowered Ionis Pharmaceuticals from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $67.00 to $60.00 in a research report on Friday, August 2nd. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Ionis Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $60.65.

Ionis Pharmaceuticals Trading Up 0.2 %

NASDAQ IONS opened at $34.01 on Friday. Ionis Pharmaceuticals, Inc. has a 52-week low of $33.33 and a 52-week high of $54.44. The firm has a 50-day moving average price of $38.87 and a 200 day moving average price of $42.52. The stock has a market capitalization of $5.37 billion, a P/E ratio of -13.94 and a beta of 0.39. The company has a quick ratio of 8.82, a current ratio of 8.91 and a debt-to-equity ratio of 1.86.

Insider Transactions at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, EVP Eric Swayze sold 1,194 shares of the firm’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $37.92, for a total value of $45,276.48. Following the completion of the sale, the executive vice president now owns 33,713 shares of the company’s stock, valued at approximately $1,278,396.96. This trade represents a 3.42 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Brett P. Monia sold 6,630 shares of the business’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $38.05, for a total transaction of $252,271.50. Following the sale, the chief executive officer now owns 167,393 shares in the company, valued at $6,369,303.65. The trade was a 3.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 8,197 shares of company stock valued at $315,310. Corporate insiders own 2.71% of the company’s stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.